"Antiviral Activity of WIN 54954 in Coxsackievirus B2 Carrier State Infected Human Myocardial Fibroblasts."

According to the authors' abstract of an article published in Antiviral Research, "Persistent infections with a cardiotropic enterovirus, e.g., coxsackievirus B2 (CVB2), cause chronic myocarditis and eventually congestive heart failure. Therefore, the antiviral activity of WIN 54954, a capsid binding antiviral agent that inhibits enterovirus uncoating, was studied in persistently CVB2-infected cultures of human myocardial fibroblasts. Cultures displayed a typical carrier state infection with virus titers of 3.9 ± 1.6x10⁵ plaque forming units (PFU)/ml and 0.99% infected cells. WIN 54954 (0.025-1 (mu)g/ml) application was started 7 days after infection of the cultures. ...

Want to see the full article?

• Purchase this article for only $3.00